Focal radiotherapy boost to MR-visible tumor for prostate cancer: a systematic review - Top-Institutions - MDSpire

Focal radiotherapy boost to MR-visible tumor for prostate cancer: a systematic review

  • By

  • Anna M. Dornisch

  • Allison Y. Zhong

  • Darren M. C. Poon

  • Alison C. Tree

  • Tyler M. Seibert

  • January 20, 2024

  • 0 min

Share

Top Institutions in Urology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Radiation Oncology
    • Urologic Oncology
    • Medical Imaging

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Radiation Oncology
    • Urologic Oncology
    • Imaging Sciences

  • #3

    Dana-Farber Cancer Institute / Brigham and Women’s Hospital
    Dana-Farber Cancer Institute / Brigham and Women’s Hospital

    Boston, MA

    Key Differentiators

    • Radiation Oncology
    • Medical Oncology
    • Radiology

  • #4

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Radiation Oncology
    • Urology
    • Medical Imaging

  • #5

    University of Michigan Rogel Cancer Center
    University of Michigan Rogel Cancer Center

    Ann Arbor, MI

    Key Differentiators

    • Radiation Oncology
    • Urologic Oncology
    • Imaging

Original Source(s)

Focal radiotherapy boost to MR-visible tumor for prostate cancer: a systematic review

  • by Anna M. Dornisch, Allison Y. Zhong, Darren M. C. Poon, Alison C. Tree, Tyler M. Seibert

  • January 20, 2024

Related Content

The first patient-reported outcomes from the Utrecht Prostate Cohort (UPC): the first platform facilitating ‘trials within cohorts’ (TwiCs) for the evaluation of interventions for prostate cancer

Prostate Cancer Conference Highlights from ASCO GU 2025

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from GU ASCO 2025. This video highlights updates in mCRPC and oligometastatic prostate cancer trials.

  • March 3, 2025

  • 1 min
Precision Oncology in Practice: How Theranostics Personalizes Treatment

In precision oncology, theranostics stands out as a transformative approach that tailors cancer treatment to the unique molecular profile of each patient. By integrating advanced diagnostic imaging with targeted therapy, theranostics ensures that treatments are customized to the unique characteristics of each patient's cancer, thereby optimizing efficacy and minimizing adverse effects.

  • by

  • May 11, 2025

  • 4 min